Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement
Rhea-AI Summary
Profusa (Nasdaq: PFSA) reported receiving a Nasdaq Listing Qualifications Notice stating that, as of August 14, 2026, following its 1-for-4 reverse stock split, it had fewer than the 500,000 publicly held shares required under Nasdaq Listing Rule 5550(a)(4). Based on Profusa’s August 21, 2026 correspondence, Nasdaq determined the company complied with the rule as of that date and closed its review. The Notice does not affect the listing or trading of Profusa’s securities, which continue on The Nasdaq Capital Market under the symbol PFSA.
Positive
- Return to Nasdaq Rule 5550(a)(4) compliance confirmed as of August 21, 2026
- Nasdaq compliance review formally closed, reducing near-term listing uncertainty
- PFSA shares continue to trade on The Nasdaq Capital Market with no listing interruption
Negative
- Prior deficiency triggered on August 14, 2026 due to fewer than 500,000 publicly held shares after reverse split
Market reaction after Nasdaq compliance update: PFSA +3.09%
Following this news, PFSA has gained 3.09%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.9% during the session. Argus tracked a trough of -10.7% from its starting point during tracking. Our momentum scanner has triggered 12 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $3.02. Trading volume is exceptionally heavy at 26.4x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 20 | Q2 earnings report | Negative | -44.2% | Q2 losses, liabilities, and working-capital borrowing accompanied acquisition progress. |
| Aug 13 | Reverse stock split | Neutral | -1.5% | Company announced a 1-for-4 reverse stock split effective August 17. |
| Jul 31 | Acquisition option agreement | Neutral | -9.2% | Company obtained an option to acquire G3 Vision Labs and subsidiaries. |
| Jul 27 | Acquisition term sheet | Neutral | -28.6% | Company announced a non-binding term sheet and management changes. |
| Jul 02 | Reverse stock split | Neutral | -28.1% | Company announced a 1-for-25 reverse stock split effective July 7. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
PFSA's recent news events were followed by negative price reactions, with one aligned negative event and four divergences on neutral or positive announcements.
Key Terms
reverse stock split financial
forward-looking statements regulatory
safe harbor regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Berkeley, CA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced that it has received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that on August 14, 2026, following the effectiveness of the Company’s 1-for-4 reverse stock split, the Company had less than the 500,000 publicly held shares required under Nasdaq Listing Rule 5550(a)(4) (the “Rule”). The Notice further stated that based on the Company’s correspondence with Nasdaq on August 21, 2026, Nasdaq has determined that the Company complies with the Rule as of August 21, 2026, and that Nasdaq’s review of the Company’s compliance with the Rule is now closed.
The Notice has no effect on the listing or trading of the Company’s securities, which continue to trade on The Nasdaq Capital Market under the symbol “PFSA.”
This announcement is made in accordance with Nasdaq Listing Rule 5810(b), which requires prompt public disclosure of receipt of a deficiency notification.
About Profusa, Inc.
Based in Berkeley, California, Profusa is a digital health company developing a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
Forward Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, without limitation, the timing and completion of the reverse split. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Investor and Media Contacts:
email: info@coreir.com
phone: 1(212) 655-0924
